Yoga guru Ramdev’s Patanjali Ayurved Ltd on Tuesday launched what they claimed was the first Ayurvedic medicine to cure Covid-19. However, the AYUSH Ministry has sought details about the medicine and has directed Patanjali and Ramdev to stop advertising such claims.
At the launch in Haridwar, Ramdev claimed that ‘Coronil tablet’, ‘Swasari Vati’ and ‘Anu Taila’ had shown “100 per cent favourable results” during clinical trials on Covid-19 patients. He claimed that a clinical controlled study was done in Delhi, Ahmedabad, Meerut and other cities. During the trial, he claimed, 69 per cent patients recovered in 3 days, while the recovery rate over a period of seven days was 100 per cent.
Taking cognizance of the news, The AYUSH Ministry in a statement said, “Facts of the claim and details of the stated scientific study are not known to the Ministry.”
The statement says that Patanjali Ayurved Ltd has been asked to provide at the earliest the details of the name and composition of the medicines being claimed will treat Covid-19; the site(s)/hospital(s) where the research study was conducted; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results data of the study(ies) and to stop advertising/publicising such claims till the issue is duly examined.
The ministry has also requested the Uttarakhand State Licensing Authority to provide copies of the license and product approval details of the Ayurvedic medicines which the company has claimed will treat Covid-19.
On June 2, the AYUSH Ministry had issued a circular to the principal secretaries of all states to take necessary action “against instances of misleading information, fake claims and misbranding”.
“I would like to inform that the following activities are tantamount to contravention of legal provisions: false claims and publicising so called approval of research study or product manufacturing about COVID19 control,” the circular, signed by AYUSH Ministry Additional Secretary Pramod Kumar Pathak stated.
The ministry also directed that “a warning may be issued and if not complied in one week time, FIR may be filed in blatant cases of violation”.
During the launch Tuesday, Ramdev also claimed that the medicine, manufactured by Haridwar-based Divya Pharmacy and Patanjali Ayurved Ltd, is the result of a joint research of Patanjali Research Institute and National Institute of Medical Sciences and Research, NIMS University, Jaipur.
NIMS University chairman Balbir Tomar said all the parameters of research were followed.— With ENS, Delhi.